Piyapharom Intarawichian

Dr. Piyapharom Intarawichian

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2022 in HPB
Verified
Journal Article
Open access
PSPrakasit Sa-Ngiamwibool
Prakasit Sa-Ngiamwibool
CAChaiwat Aphivatanasiri
Chaiwat Aphivatanasiri
SSSakkarn Sangkhamanon
Sakkarn Sangkhamanon
PIPiyapharom Intarawichian
Piyapharom Intarawichian
WKWaritta Kunprom
Waritta Kunprom
SKSupinda Koonmee
Supinda Koonmee
Intrahepatic cholangiocarcinoma (iCCA) arises from bile ducts within the liver. Thailand has the highest incidence of CCA worldwide, with a high mortality rate. Early diagnosis and accurate prognostic stratification can improve overall survival. We aim to modify the AJCC/UICC 8th edition staging system for iCCA by creating the Khon Kaen University (KKU) staging system for more precise patient stratification and prognostic prediction. A total of 298 iCCA patients who underwent hepatectomy were included in this retrospective study at the Srinagarind Hospital, Khon Kaen University, Thailand. Univariate and multivariate analysis were performed to examine survival rate, hazard ratio, and prognostic factors. Univariate and multivariate analysis of the cohort showed that growth patterns, histological type, histological grade, lymph node metastasis and distant metastasis were independent prognostic factors when compared to the respective reference groups. The 8th AJCC staging system incorporated growth patterns into the KKU staging system. This model modified AJCC stages I, II, and III for better prediction of patient survival. Growth patterns were incorporated to improve the 8th AJCC staging system for prognostication of iCCA patients in Northeast Thailand. We propose the KKU staging system as an alternative model for iCCA staging to augment the accuracy of survival prognostication.

2 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NKNatcha Khuntikeo
Natcha Khuntikeo
SPSureerat Padthaisong
Sureerat Padthaisong
WLWatcharin Loilome
Watcharin Loilome
PKPoramate Klanrit
Poramate Klanrit
SRSoontaree Ratchatapusit
Soontaree Ratchatapusit
ATAttapol Titapun
Attapol Titapun
Background: The mismatch repair (MMR) system prevents DNA mutation; therefore, deficient MMR protein (dMMR) expression causes genetic alterations and microsatellite instability (MSI). dMMR is correlated with a good outcome and treatment response in various cancers; however, the situation remains ambiguous in cholangiocarcinoma (CCA). This study aims to evaluate the prevalence of dMMR and investigate the correlation with clinicopathological features and the survival of CCA patients after resection. Materials and Methods: Serum and tissues were collected from CCA patients who underwent resection from January 2005 to December 2017. Serum OV IgG was examined using ELISA. The expression of MMR proteins MLH1, MSH2, MSH6 and PMS2 was investigated by immunohistochemistry; subsequently, MMR assessment was evaluated as either proficient or as deficient by pathologists. The clinicopathological features and MMR status were compared using the Chi-square test. Univariate and multivariate analyses were conducted to identify prognostic factors. Results: Among the 102 CCA patients, dMMR was detected in 22.5%. Survival analysis revealed that dMMR patients had better survival than pMMR (HR = 0.50, p = 0.008). In multivariate analysis, dMMR was an independent factor for a good prognosis in CCA patients (HR = 0.58, p = 0.041), especially at an early stage (HR = 0.18, p = 0.027). Moreover, subgroup analysis showed dMMR patients who received adjuvant chemotherapy had better survival than surgery alone (HR = 0.28, p = 0.012). Conclusion: This study showed a high prevalence of dMMR in cholangiocarcinoma with dMMR being the independent prognostic factor for good survival, especially in early-stage CCA and for patients who received adjuvant chemotherapy. dMMR should be the marker for selecting patients to receive a specific adjuvant treatment after resection for CCA.

13 December 2022 in Acta Cytologica
Verified
Journal Article
Closed access
PDF file
NSNatruja Sridakhun
Natruja Sridakhun
PIPiyapharom Intarawichian
Piyapharom Intarawichian
MTMalinee Thanee
Malinee Thanee
SWSasithorn Watcharadetwittaya
Sasithorn Watcharadetwittaya
Introduction: Body cavity effusions are routinely used as cytologic specimens. The distinction between metastatic carcinoma, mesothelioma, and reactive mesothelial cells remains a major challenge. Immunohistochemistry (IHC) is a supplemental method that can aid in diagnosis and often involves many markers as part of an IHC panel. Several immunohistochemical markers are now widely used. This study aims to determine the optimal immunomarkers and IHC panels to differentiate reactive mesothelial cells from metastatic cancer in body cavity fluid samples. Methods: IHC was performed for claudin-4, MOC-31, Ber-Ep4, D2-40, and calretinin on sections derived from 152 cellblocks containing effusions. The samples consisted of 16 (10.53%) benign and 136 (89.47%) malignant tumors, including 87 (63.97%) lung cancers, nine (6.62%) breast cancers, 11 (8.09%) gynecologic cancers, seven (5.15%) pancreaticobiliary cancers, and 22 (16.17%) unspecified primary malignancies. Results: Claudin-4, MOC-31, Ber-EP4, D2-40, and calretinin demonstrated sensitivities of 91.18%, 91.91%, 55.88%, 90.44%, and 98.53%, respectively. The corresponding specificities were 100.00%, 100.00%, 100.00%, 93.75%, and 100.00%. The sensitivity and specificity were both 100% when claudin-4 or MOC-31 was combined with calretinin. The combination of four markers as an IHC panel (claudin-4, MOC-31, calretinin, and D2-40) had a sensitivity of 97.79% and a specificity of 100.00%. Conclusion: Claudin-4 and MOC-31 both demonstrated significant diagnostic value in distinguishing metastatic epithelial carcinoma from reactive mesothelium. The sensitivity, specificity, and accuracy of these two markers, one of which is an epithelial marker and one of which is a mesothelial marker, reached 100%. Therefore, a combination of these two markers may be appropriate.

1 November 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
SKSupinda Koonmee
Supinda Koonmee
OSOngart Somintara
Ongart Somintara
PIPiyapharom Intarawichian
Piyapharom Intarawichian
CAChaiwat Aphivatanasiri
Chaiwat Aphivatanasiri
SSSakkarn Sangkhamanon
Sakkarn Sangkhamanon
RAReza Alaghehbandan
Reza Alaghehbandan
Purpose: Breast cancer is a growing public health challenge in Thailand. Pathum Raksa project was launched in 2015, as a result of higher than expected rate of triple-negative breast cancers in Thai women. The purpose of this project was to identify the cause(s) and address the issue(s), hence improving the quality of breast cancer biomarker testing in Thailand. Materials and Methods: Nineteen hospitals across the country, with 902 breast cancer patients were enrolled in this study during 2015– 2020. The pre- and post-data from Pathum Raksa initiative was only available for Khon Kaen University (KKU) and Udonthani hospitals in Northeast Thailand. We developed a resource-stratified strategic plan that included designing a unique specimen container, forming multidisciplinary teams from the Surgery and Pathology Departments, and employing locally developed innovative technologies to optimize the entire process of breast cancer diagnostics and biomarker testing. Results: The rate of triple-negative breast cancers in KKU and Udonthani decreased 52.8% (p = 0.02) and 28.9% (p = 0.48), respectively. The rate of ER+ breast cancers in both hospitals increased 5% post-Pathum Raksa implementation. The rate of HER2-neu+ (score 3+) also increased in both hospitals (particularly an increased 65% rate in KKU). Luminal A/B cancers were the most common subtype in both KKU and Udonthani hospitals. Conclusion: Pathum Raksa project has significantly improved breast cancer biomarker testing in Thailand. As a result of this national innovation, false-negative rates of breast biomarkers have significantly decreased, resulting in improving prognosis, treatment, and survival of breast cancer women in Thailand.

4 September 2023
Verified
Book Chapter
Closed access
PDF file
SKSupinda Koonmee
Supinda Koonmee
PSPrakasit Sa-Ngiamwibool
Prakasit Sa-Ngiamwibool
CAChaiwat Aphivatanasiri
Chaiwat Aphivatanasiri
WKWaritta Kunprom
Waritta Kunprom
PIPiyapharom Intarawichian
Piyapharom Intarawichian
MTMalinee Thanee
Malinee Thanee

1 February 2025 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
PKPonkrit Kaewkedsri
Ponkrit Kaewkedsri
PIPiyapharom Intarawichian
Piyapharom Intarawichian
SJSirawich Jessadapattarakul
Sirawich Jessadapattarakul
WKWaritta Kunprom
Waritta Kunprom
SKSupinda Koonmee
Supinda Koonmee
CAChaiwat Aphivatanasiri
Chaiwat Aphivatanasiri
Purpose: This study aims to investigate the clinicopathological characteristics of triple-negative breast cancer (TNBC) in relation to programmed cell death ligand 1 (PD-L1) and major histocompatibility complex class I (MHC class I) expression, with a focus on their prognostic significance. Patients and Methods: A retrospective analysis was conducted on formalin-fixed paraffin-embedded (FFPE) tissue samples from 148 TNBC patients diagnosed between 2008 and 2021. Immunohistochemical analysis evaluated PD-L1 and MHC class I expression. PD-L1 was assessed using Combine Positive Scores (CPS), with the threshold set at CPS ≥ 1 and CPS ≥ 10. MHC class I expression was categorized into low and high levels. Associations between these markers, clinicopathological features, overall survival (OS), and disease-free survival (DFS) were analyzed. PD-L1 expression was also compared between older FFPE blocks (2008– 2018) versus newer blocks (2019– 2021). Results: PD-L1 expression was observed in 29.1% of cases with a Combined Positive Score (CPS) ≥ 1 and 8.8% of CPS ≥ 10 cases. MHC class I expression was evenly split between low and high levels. Older FFPE blocks (2008– 2018) showed lower PD-L1 expression than newer blocks (2019– 2021). There was no significant association between PD-L1 expression and overall survival (OS) or disease-free survival (DFS). However, high MHC class I expression was strongly associated with improved OS (HR = 0.469, 95% CI: 0.282– 0.780, p=0.004). Patients with negative PD-L1 and high MHC class I expression had the most favorable prognosis, with significant OS for CPS ≥ 1 (HR = 0.447, 95% CI: 0.236– 0.846, p=0.013) and CPS ≥ 10 (HR = 0.516, 95% CI: 0.307– 0.869, p=0.013). Conclusion: These findings support the potential of PD-L1 and MHC class I expression as prognostic markers for TNBC, offering insights to guide treatment decisions and improve patient outcomes.